1-3 of 3
Yui Kyogoku
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Tadashi Matsushita, Nobuaki Suzuki, Chiai Nagae, Azusa Nagao, Masahiko Ando, Yachiyo Kuwatsuka, Daisuke Nosaka, Yui Kyogoku, Tomomi Shimura, Keiji Nogami
Journal: Blood
Blood (2023) 142 (Supplement 1): 2625.
https://doi.org/10.1182/blood-2023-173071
Published: 2023
Journal Articles

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Chiai Nagae, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Hiroki Oki, Keisuke Iwasaki, Keiji Nogami
Journal: Blood
Blood (2023) 142 (Supplement 1): 3991.
https://doi.org/10.1182/blood-2023-173073
Published: 2023
Journal Articles

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Keisuke Iwasaki, Keiji Nogami
Journal: Blood
Blood (2022) 140 (Supplement 1): 2742–2744.
https://doi.org/10.1182/blood-2022-157249
Published: 2022